Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05251792
Other study ID # 2020KYPJ82
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 11, 2021
Est. completion date December 30, 2024

Study information

Verified date February 2022
Source Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact Zhihong Huang, M.D
Phone +8602066615461
Email 575772588@qq.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia. Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear. Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma. This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage


Description:

Observation index: Visual acuity,Intraocular pressure,Ophthalmoscope,MPOD,Visual field and OCT. Inspection parameters of OCT: 1. Retinal nerve fiber layer thickness 2. Ganglion cell complex thickness 3. Mean thickness of the central retina 4. Mean defect


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 90 Years
Eligibility Inclusion Criteria: - Experimental group: - (1) According to the diagnostic criteria of PACD - (2)History of peripheral iridectomy or trabeculectomy - (3)Over 40 - (4)Phakic eyes - (5)Intraocular pressure is less than 21mmhg, more than one week - (6)Eyes with clear optical media. - Control group: - (1)No history of glaucoma and other eye diseases - (2)Phakic eyes - (3)Over 40 - (4)Intraocular pressure10~21mmHg Exclusion Criteria: - (1)History of corneal diseases - (2)History of eye tumor or other ophthalmic surgery - (3)Cataract - (4)Taking supplements containing lutein within 6 months - (5)Snellen's visual acuity was less than 6 / 20,the diopter is beyond ± 6 degrees

Study Design


Intervention

Other:
Ocular examination
All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement

Locations

Country Name City State
China Zhognshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhongshan Ophthalmic Center, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Macular Pigment Optical Density(MPOD)Measurement A one-wavelength fundus reflectance method (Visucam 200; Carl Zeiss Meditec) was used for the detection of MPOD as previously described. The right or left eye was randomly selected for measurement. The parameters and profiles of MPOD in a 7-degree eccentricity that corresponded to a 4 mm diameter were evaluated and output. Parameters included max and mean optical density (OD), volume, and area. MaxOD and MeanOD with units "d.u." (initial of density units) were used for the analyses. 3 months after surgery
Primary Retinal nerve fiber layer thickness Detection by optical coherence tomography (OCT). Circumpapillary RNFL scans were obtained using the standard 3.4 mm 12-degree circumpapillary nerve fiber layer scan protocol.We recorded superior, inferior, nasal, temporal, and total RNFL thickness. 3 months after surgery
Primary Ganglion cell complex (GCC)thickness Detection by optical coherence tomography (OCT). The distance from the internal limiting membrane and outer edge of the outer plexiform layer was defined as GCC thickness. 3 months after surgery
Primary Mean central retina thickness Detection by optical coherence tomography (OCT). CRT thickness was defined as distance between the internal limiting membrane and the inner edge of the retinal pigment epithelium. 3 months after surgery
Primary Mean outer retinal thickness Outer retinal (OR) thickness was calculated by subtracting GCC thickness from CRT. 3 months after surgery
Primary Visual Field Test The visual field test uses the 30-2 Threshold Test on the Humphrey Visual Field Analyzer.According to the mean deviation (MD) values generated by the software, three groups of disease severity were classified: the mild group with MD > -6 dB, the moderate group with MD between -6 and -12 dB, and the severe group with MD < -12 dB 3 months after surgery
Secondary Visual acuity Use Snellen visual acuity chart to measure naked eye vision and best corrected vision 3 months after surgery
Secondary Intraocular pressure Using non-contact tonometer (NCT) measuring intraocular pressure 3 months after surgery
Secondary Cup/ Disk ( C/ D) determine the cup to disc ratio by ophthalmoscope 3 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A